At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 63 enrolled
Drug / intervention
AdreView (Iobenguane I 123 Injection)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)
In Brief
A Phase 4 clinical trial evaluating AdreView (Iobenguane I 123 Injection) for Heart Failure (HF) and Ventricular Dysfunction, Left. Completed, enrolled 63 participants across 1 site.
Detailed Summary
The aim of the study was to assess the reproducibility of quantitative measurements of myocardial uptake of Iobenguane I 123 on planar and single photon emission computed tomography (SPECT) imaging following intravenous (i.v.) administration of AdreView. Efficacy was assessed based upon the absolute differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days apart.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure (HF), Ventricular Dysfunction, Left
CountriesUnited States
CollaboratorsH2O Clinical LLC, Quintiles, Inc.
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedSep 2013
Primary CompletionFeb 2014
TodayJul 2026
First PostedSep 6, 2013
Enrollment StartAug 1, 2013
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.8 years ago
Interventions
AdreView (Iobenguane I 123 Injection)drug
AdreView 10 mCi as a single i.v administration